This study is testing a new medication called Brilaroxazine (RP5063) for people with schizophrenia. Researchers want to see how safe and effective Brilaroxazine is compared to a placebo (a pill with no medicine) in both the short-term (4 weeks) and long-term (52 weeks). Brilaroxazine is a new drug that has not yet been approved for use. You might be able to join if you are 18 to 65 years old, have a diagnosis of schizophrenia, and meet other specific health requirements. The study aims to understand if Brilaroxazine can help manage symptoms of schizophrenia. The current status of this study is unclear.

Study design

This is a randomized, double-blind, placebo-controlled study involving up to 690 participants. It compares Brilaroxazine at fixed doses (15 mg or 50 mg) to a placebo for 28 days, followed by a 52-week open-label treatment period with flexible doses (15, 30, or 50 mg).

What's involved

Participants will receive Brilaroxazine or a placebo daily for 28 days, followed by daily Brilaroxazine for 52 weeks. The total study duration is 56 weeks.

Compensation

Not stated in the trial record.

Follow-up

The study measures safety and effectiveness for 28 days (double-blind) and then for 52 weeks (open-label).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.